Pilocarpine Ionic Liquid Analog for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pilocarpine formulations for glaucoma treatment suffer from instability and reduced efficacy due to epimerization in aqueous solutions, leading to decreased potency and increased cytotoxicity.
Innovation Solution
Development of pilocarpine ionic liquid analogs, such as [Pilo-OEG]Cl, which exhibit enhanced stability, cytocompatibility, and permeability through the cornea, formed by reacting pilocarpine with oligoethylene glycol derivatives, resulting in improved structural stability and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If pilocarpine is delivered in its salt forms (chloride or nitrate) which exhibit good aqueous solubility, then solubility is improved, but the compound readily epimerizes in aqueous solution via hydrolytic opening of its lactone moiety, leading to reduced stability
Solution Approach 1:
The patent transforms pilocarpine from a traditional salt form to an ionic liquid form by modifying the molecular structure. Specifically, the pilocarpine molecule is converted to an ionic liquid cation with a chloride anion, changing the physical and chemical parameters of the compound. This structural transformation allows the compound to maintain high aqueous solubility while preventing epimerization and hydrolytic degradation, thus resolving the contradiction between solubility and stability.
Solution Approach 2:
The invention creates a composite ionic liquid structure combining the pilocarpine-derived cation with a chloride anion. This composite molecular architecture provides both the solubility benefits of ionic compounds and the stability of the closed lactone ring structure, eliminating the epimerization problem associated with traditional pilocarpine salt forms while maintaining good aqueous solubility.
2Stability of the object's composition
If pilocarpine undergoes epimerization in aqueous solution, then structural stability deteriorates, but this leads to decreased potency and increased cytotoxicity
Solution Approach 1:
By converting pilocarpine to an ionic liquid form, the patent fundamentally changes the molecular parameters to prevent epimerization. The ionic liquid structure with its charged nature and specific molecular architecture stabilizes the lactone ring, preventing hydrolytic opening and epimerization. This eliminates the formation of epimerized degradation products that cause cytotoxicity, thereby resolving the contradiction between structural stability and cytotoxicity.
3Ease of manufacture
If traditional pilocarpine formulations are used, then ease of manufacture is maintained, but potency is reduced due to epimerization
Solution Approach 1:
The patent modifies the manufacturing approach by synthesizing pilocarpine ionic liquid through a straightforward chemical transformation of pilocarpine. The process involves reacting pilocarpine with appropriate reagents to form the ionic liquid cation, followed by anion exchange to introduce chloride. This modified manufacturing process, while slightly more complex than traditional salt formation, provides a stable product with consistent high potency, resolving the contradiction between manufacturing ease and therapeutic reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
[Pilo-OEG]Cl demonstrates 2-fold higher potency in reducing intraocular pressure compared to pilocarpine hydrochloride, with improved stability and cytocompatibility, making it a promising new drug candidate for glaucoma therapy.
Implementation Method 1
enhanced stability, cytocompatibility, and permeability through the cornea
Data Source
AI summary
The present disclosure provides pilocarpine ionic liquid analogs useful in the treatment of ophthalmological disorders such as glaucoma.